Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage forms comprising a plasma kallikrein inhibitor

Dosage forms comprising a plasma kallikrein inhibitor

US Patent 11234939 · Granted Feb 1, 2022

Estimated economic value: $9,217,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Allergenic protein formulations for immunotherapy2024
Allergenic protein formulations for immunotherapy2024
Methotrexate formulation2023
Solid forms of a plasma kallikrein inhibitor and salts thereof2023
In vitro method for determining the adsorbing capacity of an insoluble adsorbant2023
Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagoni2022
Methotrexate formulation2021
Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagoni2020
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2020
Pharmaceutical compositions2019
Ocular iontophoretic delivery of dexamethasone and formulations thereof2019
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2018